Last reviewed · How we verify

NCT04343898: STOP-COVID

Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19

Completed Last updated 9 August 2023
What this trial tests

trial testing No intervention in Coronavirus Infection in 5,154 participants. Completed in 1 July 2023.

Timeline
1 April 2020
Primary endpoint
1 August 2020
1 July 2023

Quick facts

Lead sponsorBrigham and Women's Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment5,154
Start date1 April 2020
Primary completion1 August 2020
Estimated completion1 July 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Brigham and Women's Hospital

Who can join

18 and older, any sex, with Coronavirus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicenter observational/registry study of the clinical features and outcomes of critically ill patients with COVID-19.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19.
    Gupta S, Coca SG, Chan L, Melamed ML, et al · · 2021 · cited 215× · PMID 33067383 · DOI 10.1681/asn.2020060897
  2. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study.
    Hayek SS, Brenner SK, Azam TU, Shadid HR, et al · · 2020 · cited 102× · PMID 32998872 · DOI 10.1136/bmj.m3513
  3. Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States.
    Molnar MZ, Bhalla A, Azhar A, Tsujita M, et al · · 2020 · cited 83× · PMID 32844546 · DOI 10.1111/ajt.16280
  4. Implementation of the trial emulation approach in medical research: a scoping review.
    Scola G, Chis Ster A, Bean D, Pareek N, et al · · 2023 · cited 25× · PMID 37587484 · DOI 10.1186/s12874-023-02000-9
  5. Relationship Between Preexisting Cardiovascular Disease and Death and Cardiovascular Outcomes in Critically Ill Patients With COVID-19.
    Vasbinder A, Meloche C, Azam TU, Anderson E, et al · · 2022 · cited 21× · PMID 36193749 · DOI 10.1161/circoutcomes.122.008942
  6. The Impact of Chronic Kidney Disease on Outcomes of Patients with COVID-19 Admitted to the Intensive Care Unit.
    Brogan M, Ross MJ. · · 2022 · cited 19× · PMID 34634789 · DOI 10.1159/000519530
  7. Acute Kidney Injury in the Time of COVID-19.
    Chan L, Coca SG. · · 2020 · cited 12× · PMID 35372928 · DOI 10.34067/kid.0003722020
  8. MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID-19 severe respiratory failure (MUST COVID): A retrospective cohort study.
    Barrett CD, Moore HB, Moore EE, Benjamin Christie D, et al · · 2022 · cited 6× · PMID 35341072 · DOI 10.1002/rth2.12669

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Coronavirus Infection

Currently open trials in the same condition.

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04343898.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing